

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 20 July 2000 (20.07.00)	
International application No. PCT/AU99/01048	Applicant's or agent's file reference 7462296
International filing date (day/month/year) 24 November 1999 (24.11.99)	Priority date (day/month/year) 24 November 1998 (24.11.98)
Applicant NOTTLE, Mark, Brenton et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
30 May 2000 (30.05.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Claudio Borton Telephone No.: (41-22) 338.83.38
--	---



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ :

A01N 1/02, A01K 67/02

A1

(11) International Publication Number:

WO 00/30441

(43) International Publication Date:

2 June 2000 (02.06.00)

(21) International Application Number: PCT/AU99/01048

(22) International Filing Date: 24 November 1999 (24.11.99)

(30) Priority Data:

PP 7299

24 November 1998 (24.11.98) AU

(71) Applicants (for all designated States except US): BRESAGEN LIMITED [AU/AU]; 38-39 Winwood Street, Thebarton, S.A. 5031 (AU). THE UNIVERSITY OF QUEENSLAND [AU/AU]; St. Lucia, QLD 4067 (AU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): NOTTLE, Mark, Brenton [AU/AU]; Lep P Alexander Avenue, RSD Bibaringa, S.A. 5118 (AU). CAMERON, Randal [AU/AU]; 7 Teague Street, Indooroopilly, QLD 4068 (AU). BEEBE, Luke, Francis, Sharkerley [AU/AU]; 32 Watson Street, Wilson, QLD 4051 (AU). BLACKSHAW, Alan, Weaver [AU/AU]; 13 Jenkinson Street, Indooroopilly, QLD 4068 (AU). NAGASHIMA, Hiroshi [JP/JP]; 2-20-19, Mukaibara, Asao, Kawasaki, Kanagawa 215-0007 (JP).

(74) Agents: STEARNE, Peter et al.; Davies Collison Cave, Level 10, 10 Barrack Street, Sydney, NSW 2000 (AU).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: CRYOPRESERVATION OF OOCYTES AND EMBRYOS AND METHODS FOR PRODUCING ANIMALS INVOLVING THE SAME

(57) Abstract

A method for the cryopreservation of oocytes or embryos, which comprises centrifugation of oocytes or embryos to polarise cytoplasmic lipid outside the oocyte or embryonic cells, subjecting the oocytes or embryos to low temperature conditions in the presence of a cryoprotectant which results in freezing of the oocytes or embryos prior to lipid depolarisation, followed by low temperature storage of the frozen lipid polarised oocytes or embryos are described, as are oocytes and embryos produced according to such methods, and methods for producing live animals.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**CRYOPRESERVATION OF OOCYTES AND EMBRYOS
AND METHODS FOR PRODUCING ANIMALS INVOLVING THE SAME**

The present invention relates to methods for the cryopreservation of oocytes and embryos,
5 use of oocytes and embryos, and methods for producing live animals from such embryos.

The production of live animals from frozen thawed embryos has been described for a number of species including cattle and sheep.

10 However the production of live animals such as piglets from frozen/thawed oocytes and embryos remains problematic. In relation to pigs for example, a small number of piglets have been produced using conventional techniques and all have been from perihatching embryos, and not zona intact porcine embryos. The perihatching embryo stage is unsuitable for most uses because the embryos are not surrounded by an intact zona pellucida and are
15 subject to bacterial and viral infection. This is an all important requirement for the import/export of genetic material. Such protocols require embryos to be surrounded by an intact zona pellucida because it protects against bacterial and viral infection as mentioned above, thus reducing the risk of disease transmission.

20 In other animals such as companion animals (for example dogs and cats), and domestic/livestock animals (for example horses, goats, llamas and alpacas), the production of live animals from frozen/thawed oocytes and embryos has been very problematic with a low success rate. This is largely because early stage embryos for most species contain significant levels of lipid.

25

The successful cryopreservation of animal oocytes and embryos, remains largely illusionary. In pigs in particular, cryopreservation techniques used for cryopreservation of embryos from other species are generally not successful.

30 In one prior proposal, animal embryos were subject to conditions which reduce the level of lipid in the embryo. In this proposal lipid was forced from the embryonic cells, resulting in a layer of lipid between the blastomeres and the zona pellucida. This lipid was moved by

- 2 -

aspirating a lipid from the embryo using micro manipulation techniques. Removing lipids from embryos requires considerable technical skill, as well as much complexity.

The present invention seeks to overcome the problems associated with cryopreservation of oocytes and embryos, and seeks to provide simple, convenient and easily performed methods for the cryopreservation of oocytes and embryos, such as zona intact porcine embryos, and for producing live animals therefrom.

Summary of Invention

10 In accordance with a first aspect of this invention there is provided a method for the cryopreservation of oocytes or embryos, which comprises centrifugation of oocytes or embryos to polarise cytoplasmic lipid outside the oocyte or embryonic cells, subjecting the oocytes or embryos to low temperature conditions in the presence of a cryoprotectant which results in freezing of the oocytes or embryos prior to lipid depolarisation, followed by low
15 temperature storage of the frozen lipid polarised oocytes or embryos.

Preferably, the oocytes or embryos are vitrified by freezing in liquid nitrogen or other very cold fluid or gas which allows rapid temperature reduction.

20 In accordance with another aspect of this invention there is provided a method for producing animals from embryos which comprises thawing a cryopreserved lipid polarised embryo and thereafter transferring the embryo to a synchronised recipient female, and allowing the embryo to develop to term to give rise to live animals.

25 Detailed Description of the Invention

The present invention provides for the cryopreservation of animal embryos, for example zona intact porcine embryos, which hitherto have not been amenable to cryopreservation, and more particularly the successful production of animals from the cryopreseved embryos.

Cryopreserved oocytes can, on thawing, be fertilised, or genetically manipulated and
30 fertilised, and then transferred into a pregnancy competent female to give live animals.

- 3 -

The inventors have surprisingly found that centrifugation of oocytes and embryos, such as zona intact porcine embryos, which polarises cytoplasmic lipid outside the oocyte and embryonic cells, followed by exposure to low temperature conditions, preferably vitrification, in the presence of cryoprotectant, enables successful cryopreservation of the
5 polarised oocytes and embryos which maintains their viability such that on implantation into the uterus of a pregnancy competent female animals, progeny animals can develop. Accordingly, in a first aspect of this invention there is provided a method for the cryopreservation of animal oocytes embryonic cells comprising centrifugation of oocytes and embryos to polarise cytoplasmic lipid outside the oocyte or embryonic cells, subjecting
10 the oocytes or embryos to low temperature conditions in the presence of a cryoprotectant which results in freezing of the embryo prior to lipid depolarisation, followed by low temperature storage of the frozen lipid polarised oocyte or embryo cells.

Embryos which may be subject to the methods of the present invention include zona intact
15 embryos (blastomeres) from the oocyte stage, through to late blastocysts, including morulae to mid-blastocysts stage, and hatched (non-zona intact) blastocysts.

Oocytes and embryos may be from any animal, that is any mammal, including companion animals (for example dogs and cats), domestic/livestock animals (for example horses, cows,
20 sheep, goats, pigs, llamas, and alpacas), laboratory animals (for example mice, rats, and monkeys), and humans. In a preferred aspect the invention relates to pigs, that is pig oocytes and embryos.

Oocytes and embryos may be recovered from donor animals by surgical or non-surgical
25 methods. Non surgical methods can be used to recover oocytes and embryos from live cattle, but surgical methods are used for recovery from some other live animals, including pigs. For example, embryos may be surgically recovered from pigs within one to six days following mating. Alternatively, for livestock animals, oocytes and embryos may be flushed from reproductive tracts of slaughtered female animals. A second alternative is to obtain
30 immature oocytes from the ovaries of slaughtered animals, and mature and fertilise them in vitro. The embryos obtained by any of these procedures may be briefly cultured in a medium standardly used for oocyte and/or embryo culture to an appropriate stage. Whilst in

- 4 -

no way essential, it is generally desirable to briefly culture embryos prior to the methods of this invention.

The oocytes and embryos are cultured in a cryoprotectant-containing solution prior to
5 vitrification. The oocyte and embryos need only be incubated in the cryoprotectant solution for a short period of time, for example from two minutes to one hour, more preferably from two minutes to 30 minutes, still more preferably from 3 minutes to 20 minutes.

Oocytes and embryos may be incubated in a cryoprotectant-containing solution either prior
10 to, during or after centrifugation, or both.

The cryoprotectant-containing solution in which oocytes and embryos are incubated either prior to, during centrifugation, or after centrifugation, may contain any standard cryoprotectant established for use in the freezing of animal oocytes and embryos, including
15 glycerol, ethylene glycol, dimethylsulfoxide, propylene glycol and polyvinyl pyrrolidine, sucrose, trehalose, Ficoll, acetamide, egg yolk and the like. The concentration of cryoprotectant is used in an amount sufficient to replace to at least some extent water within the oocyte or embryo, such that on rapid freezing ice crystal formation is prevented. By way of example, cryopreservatives may be present in an amount from 0.5M to 8M. One or more
20 cryoprotectants may be used. The time in which oocytes and embryos may be incubated in a cryoprotectant solution following centrifugation is insufficient to allow lipid repolarisation into the tissues of the oocyte or embryo.

Oocytes and embryos are centrifuged for a time sufficient to polarise cytoplasmic lipid from
25 the oocytes and embryonic cells to the outside of the cells, for example 1 to 15 minutes at 10,000 to 20,000g. The time period of centrifugation will depend upon the centrifugal force applied during centrifugation. At a centrifugal force of about 13000g polarisation takes place after about 8 minutes of centrifugation. It may be more convenient to centrifuge the oocytes and embryos in the presence of embryo culture medium, rather than in the presence
30 of more viscous cryoprotective-containing solutions.

- 5 -

Culture medium and cryoprotectant-containing solution for culture either before or after centrifugation may contain inhibitors of actin polymerisation such as Cytochalasin B which relaxes cytoskeletal elements.

5 Following centrifugation to polarise lipid, the lipid polarised oocytes and embryos are subject to low temperature conditions in the presence of a cryoprotectant which results in freezing of the oocyte or embryo prior to lipid depolarisation. By lipid depolarisation is meant the return of lipid to the cells which lipid was polarised outside the cells by centrifugation. It is to be noted that on polarisation cytoplasmic lipid may be attached to
10 cells but displaced outside the cells.

Low temperature conditions may be provided by slow cooling, rapid freezing and vitrification. In these techniques the oocyte or embryo is frozen before the lipid returns to the cells. Vitrification may take place by placing the oocytes or embryos in a vessel, and
15 plunging the vessel into an extremely cold environment, such as liquid nitrogen or other liquefied and/or gaseous extremely cold substance. Alternatively, a vessel containing oocytes or embryos may be rapidly frozen in an ultra-cold freezer, for example at temperatures below about -30°C. Any other apparatus or methods that enable rapid freezing may be used. In one example, oocytes or embryos may be loaded into a straw which is heat
20 sealed, and then plunged into liquid nitrogen. In another example, embryos may be pulled by capillary action into a open pulled straw, which is then plunged into liquid nitrogen and subsequently stored (Vajta et al (1997) Cryoletters 18 191-5).

Oocytes and embryos may be stored in a conventional freezer facility, at temperatures, for
25 example, from -10°C to -70°C or more.

Frozen lipid polarised oocytes or embryos may be thawed according to conventional oocyte and embryo thawing techniques, such as incubation of a frozen straw at a temperature of 35°C to 39°C in a suitable culture medium. Thawed embryos may be washed in culture
30 medium, further cultured briefly, and then transferred to a synchronised recipient female, such as to the uterus of a pregnancy competent female animal. At the conclusion of

- 6 -

pregnancy term, that is embryo development to term, the introduced embryos have developed to live animals.

The present invention provides a simple and straight forward procedure for cryopreservation of oocytes and embryos, particularly zona intact frozen embryos. On thawing and implantation of the embryos into the uterus of a pregnancy competent animal, animals may be produced in a manner which has not been achievable by the prior art.

In accordance with another aspect there is provided an animal when produced from an oocyte (subsequently fertilised) or embryo which has been cryopreserved in accordance with the invention hereinbefore described.

Oocytes or embryos may be subject to genetic manipulation prior to the process of this invention. In this regard one or more genes of interest may be inserted into an oocyte or embryo by established techniques, such as using pronuclear microinjection, homologous recombination using embryonic stem cell technologies and other established techniques for introducing genes into oocytes and embryos (Nottle et al (1997), Reprod Fertil Suppl 52, 237-244.

This invention allows banks or libraries of embryos or oocytes to be prepared. These banks or libraries may be provided in frozen form and presented in a convenient manner. Examples include a straw or tube, and a plurality of straws or tubes with multiple oocytes or embryos. The bank or library may contain oocytes or embryos from different animals and may find use in artificial insemination and breeding programs.

25

Certain embodiments of the present invention will now be exemplified with reference to the following non-limiting examples.

Example 1

30 Porcine embryos were collected and washed thoroughly in culture medium (mPB1 - Quinn et al (1982) J. Reprod. Fert. 66:161-168) of 39°C three times.

- 7 -

The embryos, in the early blastocyst stage were cultured for 40 minutes in the standard embryo culture medium NCSU-23 (Peters & Reed (1991), *Theriogenology* **35**, 253) with 10% foetal bovine serum (FBS) containing 7.5µg/ml Cytochalasin B at 39°C in a humidified environment of 5% CO₂ and air. After a five minute period of cooling from 39°C to 25°C, 5 the embryos were cultured for 5 minutes in 6% BSA in BECM-3h, and then washed in 25% VS3a for approximately three minutes (VS3a containing 6.5 m glycerol, 6% bovine serum albumin in BECM-3h (Dobrinsky et al (1996) *Biol. Reprod.* **55**: 1069-1074). The embryos were centrifuged in a 1.5 Eppendorf tube (in the same media) at 13000g for about 12 minutes, recovered back into 25% VS3a, and then left in that media for a further five 10 minutes. The embryos were then washed for 30 seconds in 65% VS3a, followed by a wash in 1ml VS3a before being loaded into a straw, heat sealing the straw, and plunging the embryos in the straw into liquid nitrogen.

In an alternative to storage in a heat-sealed straw, the embryos following a wash in the 15 vitrification solution, are placed into a small drop of vitrification solution and drawn by capillary action into a narrowed hand pulled 0.25ml freezing straw (unsealed pulled straw, UPS). The straw is then plunged directly into liquid nitrogen.

Results of one experiment are set forth in Table 1.

TABLE 1

Freezing Method	Experimental Replicates	Embryo Stage	Embryo Number	Number viable (%) with blastocoels after culture for	
				24h	48h
Standard freezing method (BEVS)	2	Mor	4	0	0
	2	MBI	17	0	0
	2	Peri	13	2(15.4)	2(15.4)
BEVS/Sp	2	Mor	11	5(45.5)	6(54.6)
	3	MBI	43	27(62.8)	26(60.5)
BEVS/UPS	3	Peri	17	10(58.8)	10(58.8)
BEVS/Sp/UPS	2	Mor	6	3(50)	5(83.3)
	5	MBI	44	33(75)	28(63.6)

5 TABLE 1

Survival of Porcine Embryos frozen at various stages, thawed and then cultured for 48h. The morphological stages examined were Mor, morulae, MBI, early to mid blastocysts; Peri, peri-hatching blastocysts. The treatment used were BEVS, Beltsville embryo vitrification system (Dobrinisky et al (1997) Theriogenology 47:, 343); Sp, centrifuged, 10 UPS, unsealed pulled straw.

Example 2Method

Embryos were collected, washed thoroughly in mPB1 and then cultured for 35 minutes in 15 NCSU-23 + 10% FBS with 7.5µg/ml Cytochalasin B at 39°C in an atmosphere of 5% CO₂ in air and 100% humidity. Morulae to middle blastocyst stages were centrifuged at 13000g for the last 10 minutes of this incubation in the culture medium containing the Cytochalasin B.

- 9 -

The embryos are then transferred to 2M ethylene glycol in mPB1 at 25°C for five minutes before being washed thoroughly in 8M ethylene glycol and 7% PVP in PBS and then placed into a small droplet of the vitrification media and loaded into an unsealed pulled glass by capillary action. The straw is then plunged into liquid nitrogen and stored.

5

Thawing is by placing the end of the straw containing the embryos into 1.2mls of 1M sucrose in PBS at 39°C. By blocking the open end with a finger, the fluid containing the embryos is forced out once, thawed, by the warming of the straw. Once collected, the embryos are placed into 1M ethylene glycol in mPB1 for two minutes followed by 0.5M ethylene glycol in mPB1 for a further 2 minutes, both at 25°C. Five minutes in mPB1 at 39°C completes the rehydration procedure. The embryos can then be prepared for culture or transfer.

TABLE 2

Results

Freezing Method	Embryo Stage	Replicates	Embryo Number	Number Viable (%) with blastocoels after culture for 24hrs	48hrs
E/UPS	MB1	1	5	0(0)	0(0)
	Peri	3	18	8(44.4)	6(33.3)
E/Sp/UPS	MB1	2	14	12(85.7)	11(78.6)

15

TABLE 2

Survival of freshly collected porcine embryos, vitrified with 8m ethylene glycol and 7% PVP. Embryos stages were early to middle blastocysts (MBI) and peri-hatching blastocysts (Peri). Freezing methods were: E/UPS, vitrified in the medium described above in an unsealed pulled straw, and E/Sp/UPS, vitrified in a similar manner but centrifuged at 13000g during the last 10 minutes of the culture in NCSU-23 + Cytochalasin B (7.5µg/ml).

20

Transfer of Vitrified Embryos

The embryos once thawed using the appropriate technique are washed 3 times in mPB1 at 39°C before being held in mPB1 until just prior to transfer. They are then washed in media (PBS + 10% FBS + 2% Penicillin/Strepomycin solution (CSL: Penicillin G 5000µ/ml,

25

- 10 -

Streptomycin sulphate 5000µg/ml)) at 39°C before loading into a Tomcat Catheter attached to a 1ml syringe followed by immediate transfer into one horn of the recipient animal.

TABLE 3

5

Experiment Number	Day of Transfer	Embryonic Stage	Embryo Number	Vitrification Technique	Results thus far
1	4	Early blastocysts	37	BEVS/Sp/UPS	Returned
2	4	Early blastocysts	32	BEVS/Sp/UPS	Returned
3	4	Peri-hatching (16 hatched)	37	BEVS/UPS	Pregnant 5 piglets born alive
4	4	Peri-hatching	32	BEVS/UPS	Pregnant 3 piglets born alive

TABLE 3

Results of the transfer of porcine embryos, vitrified and thawed, into pseudopregnant recipients. Techniques used were: BEVS, Beltsville Embryo Vitrification System: Sp, centrifugation as described in methods: UPS, vitrified and stored in an unsealed pulled straw. This recipient gave birth to 5 normal healthy piglets. A fourth recipient (Experiment 4) was also confirmed pregnant at 35 days gestation and produced 3 normal healthy piglets.

The two recipients from the Experiment 2 were confirmed as not pregnant 42 days after ovulation by progesterone assay. This was followed by a return to oestrus. The third recipient (Experiment 3) was confirmed as pregnant by progesterone assay 35 days after ovulation and by detection of a uterine artery pulse.

- 11 -

TABLE 4

Recipient No.	Day of Transfer	Embryonic Stage	Embryonic Number	Results
1	4	Early blastocyst Zona intact	36	Pregnant 5 piglets born alive
2	4	Early blastocyst Zona intact	36	Delayed return
3	4	Early blastocyst Zona intact	38	Delayed return
4	4	Early blastocyst Zona intact	37	21 day return

TABLE 4

5 Results of the transfer of zona intact early blastocysts. The embryos were centrifuged during the pre-incubation period with Cytochalasin B, vitrified with 8 methyleneglycol and 7% PVP while stored in unsealed pulled straws.

Throughout this specification, unless the context requires otherwise, the word "comprise", or
10 variations such as "comprises" or "comprising" or the term "includes" or variations thereof, will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers. In this regard, in construing the claim scope, an embodiment where one or more features is added to any of claims is to be regarded as within the scope of the invention
15 given that the essential features of the invention as claimed are included in such an embodiment.

- 12 -

CLAIMS

1. A method for the cryopreservation of oocytes or embryos, which comprises centrifugation of oocytes or embryos to polarise cytoplasmic lipid outside the oocyte or
5 embryonic cells, subjecting the oocytes or embryos to low temperature conditions in the presence of a cryoprotectant which results in freezing of the oocytes or embryos prior to lipid depolarisation, followed by low temperature storage of the frozen lipid polarised oocytes or embryos.
- 10 2. A method according to claim 1 wherein the embryos are zona intact embryos.
3. A method according to claim 1 wherein oocytes and embryos are obtained from companion animals (for example dogs and cats), and domestic/livestock animals (for example horses, cows, sheep, goats, llamas and alpacas).
- 15 4. A method according to claim 3 wherein the oocytes and embryos are porcine oocytes and embryos.
5. A method according to claim 1 wherein the embryos are vitrified in the presence of a
20 solution containing one or more cryoprotectant agents.
6. A method according to claim 2 wherein the cryoprotectants are selected from dimethylsulfoxide, propylene glycol, ethylene glycol, glycerol, PVP, sucrose, trehalose, Ficoll, acetamide and egg yolk.
- 25 7. A method for producing live animals from embryos which comprises thawing a cryopreserved zona intact embryo produced according to claim 1 and thereafter introducing the embryo into the uterus or fallopian tubes of a pregnancy competent female pig which at the conclusion of pregnancy term gives rise to live piglets.
- 30 8. An animal produced from a cryopreserved oocyte or embryo produced according to claim 1.

- 13 -

9. An animal produced according to the method of claim 7.

10. An animal according to claim 7 which is a pig.

5

11. A cryopreserved oocyte or embryo when produced according to claim 1.

12. A method according to claim 3 wherein embryos are vitrified by freezing in liquid nitrogen.

10

13. A method according to claim 10 wherein oocytes or embryos are frozen in a freezing vessel including cryologic vials or freezing straws including open pulled straws in which the oocytes or embryos are located by capillary action.

15 14. A method according to claim 2 wherein the embryos are in the morulae to mid-blastocyst stage.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/01048

A. CLASSIFICATION OF SUBJECT MATTERInt Cl⁶: A01N 1/02, A01K 67/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHEDMinimum documentation searched (classification system followed by classification symbols)
IPC:A01N 1/02

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
WPAT: A01N 1/02 and cryo+**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95/05075 A (BRESATEC LIMITED) 23 February 1995 Whole document	1-14



Further documents are listed in the continuation of Box C



See patent family annex

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
14 December 1999

Date of mailing of the international search report

05 JAN 2000

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
E-mail address: pct@ipaustalia.gov.au
Facsimile No. (02) 6285 3929

Authorized officer

GAYE HOROBIN
Telephone No.: (02) 6283 2069

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/AU 99/01048

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member	
WO	95/05075	AU	74532/94
END OF ANNEX			

PATENT COOPERATION TREATY
PCT
INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 7462296	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).
International Application No. PCT/AU99/01048	International Filing Date (<i>day/month/year</i>) 24 November 1999	Priority Date (<i>day/month/year</i>) 24 November 1998
International Patent Classification (IPC) or national classification and IPC Int. Cl. ⁷ A01N 1/02, A01K 67/02		
Applicant THE UNIVERSITY OF QUEENSLAND et al		

This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.	
2.	This REPORT consists of a total of 4 sheets, including this cover sheet. <input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of sheet(s).
3. This report contains indications relating to the following items:	
I	<input checked="" type="checkbox"/> Basis of the report
II	<input type="checkbox"/> Priority
III	<input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
IV	<input type="checkbox"/> Lack of unity of invention
V	<input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
VI	<input type="checkbox"/> Certain documents cited
VII	<input type="checkbox"/> Certain defects in the international application
VIII	<input checked="" type="checkbox"/> Certain observations on the international application

Date of submission of the demand 30 May 2000	Date of completion of the report 2 February 2001
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer GAYE HOROBIN Telephone No. (02) 6283 2069

I. Basis of the report

1. With regard to the elements of the international application:*

- ☒ the international application as originally filed.
- ☐ the description, pages , as originally filed,
pages , filed with the demand,
pages , received on with the letter of
- ☐ the claims, pages , as originally filed,
pages , as amended (together with any statement) under Article 19,
pages , filed with the demand,
pages , received on with the letter of
- ☐ the drawings, pages , as originally filed,
pages , filed with the demand,
pages , received on with the letter of
- ☐ the sequence listing part of the description:
pages , as originally filed
pages , filed with the demand
pages , received on with the letter of

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, was on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/fig.

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

international application No.

PCT/AU99/01048

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims	YES
	Claims 1-14	NO
Inventive step (IS)	Claims	YES
	Claims 1-14	NO
Industrial applicability (IA)	Claims 1-14	YES
	Claims	NO

2. Citations and explanations (Rule 70.7)**NOVELTY(N) Claims 1-14**

WO 95/05075 clearly discloses methods which fall within the scope of the claims. Particular attention is directed to example 4 on page 17. Claims 1-14 cannot be considered to be novel in the light of this disclosure.

INVENTIVE STEP(IS) Claims 1-14

As above

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claim 1 is not fully supported by the description in that the claim does not include the presence of a cryoprotectant agent. The language of the description would appear to always include a cryoprotectant agent in the method of the invention.

Claim 6 lacks clarity because the cryoprotectant "Ficoll" has not been adequately identified.

Claim 13 lacks clarity. Claim 13 defines a method but it is appended to claim 10, which does not define a method.

14

PATENT COOPERATION TREATY
PCT
INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 20 FEB 2001

Applicant's or agent's file reference 7462296	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).	
International Application No. PCT/AU99/01048	International Filing Date (day/month/year) 24 November 1999	Priority Date (day/month/year) 24 November 1998
International Patent Classification (IPC) or national classification and IPC Int. Cl. ⁷ A01N 1/02, A01K 67/02		
Applicant BRESAGEN LIMITED THE UNIVERSITY OF QUEENSLAND et al		

1.	This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.																								
2.	<p>This REPORT consists of a total of 4 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheet(s).</p>																								
3.	<p>This report contains indications relating to the following items:</p> <table style="width: 100%;"> <tr> <td style="width: 5%;">I</td> <td><input checked="" type="checkbox"/></td> <td>Basis of the report</td> </tr> <tr> <td>II</td> <td><input type="checkbox"/></td> <td>Priority</td> </tr> <tr> <td>III</td> <td><input type="checkbox"/></td> <td>Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</td> </tr> <tr> <td>IV</td> <td><input type="checkbox"/></td> <td>Lack of unity of invention</td> </tr> <tr> <td>V</td> <td><input checked="" type="checkbox"/></td> <td>Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</td> </tr> <tr> <td>VI</td> <td><input type="checkbox"/></td> <td>Certain documents cited</td> </tr> <tr> <td>VII</td> <td><input type="checkbox"/></td> <td>Certain defects in the international application</td> </tr> <tr> <td>VIII</td> <td><input checked="" type="checkbox"/></td> <td>Certain observations on the international application</td> </tr> </table>	I	<input checked="" type="checkbox"/>	Basis of the report	II	<input type="checkbox"/>	Priority	III	<input type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	IV	<input type="checkbox"/>	Lack of unity of invention	V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	VI	<input type="checkbox"/>	Certain documents cited	VII	<input type="checkbox"/>	Certain defects in the international application	VIII	<input checked="" type="checkbox"/>	Certain observations on the international application
I	<input checked="" type="checkbox"/>	Basis of the report																							
II	<input type="checkbox"/>	Priority																							
III	<input type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability																							
IV	<input type="checkbox"/>	Lack of unity of invention																							
V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																							
VI	<input type="checkbox"/>	Certain documents cited																							
VII	<input type="checkbox"/>	Certain defects in the international application																							
VIII	<input checked="" type="checkbox"/>	Certain observations on the international application																							

Date of submission of the demand 30 May 2000	Date of completion of the report 2 February 2001
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer GAYE HOROBIN Telephone No. (02) 6283 2069

I. Basis of the report**1. With regard to the elements of the international application:***

- ☒ the international application as originally filed.
- ☐ the description, pages , as originally filed,
 pages , filed with the demand,
 pages , received on with the letter of
- ☐ the claims, pages , as originally filed,
 pages , as amended (together with any statement) under Article 19,
 pages , filed with the demand,
 pages , received on with the letter of
- ☐ the drawings, pages , as originally filed,
 pages , filed with the demand,
 pages , received on with the letter of
- ☐ the sequence listing part of the description:
 pages , as originally filed
 pages , filed with the demand
 pages , received on with the letter of

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, was on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/fig.

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims	YES
	Claims 1-14	NO
Inventive step (IS)	Claims	YES
	Claims 1-14	NO
Industrial applicability (IA)	Claims 1-14	YES
	Claims	NO

2. Citations and explanations (Rule 70.7)NOVELTY(N) Claims 1-14

WO 95/05075 clearly discloses methods which fall within the scope of the claims. Particular attention is directed to example 4 on page 17. Claims 1-14 cannot be considered to be novel in the light of this disclosure.

INVENTIVE STEP(IS) Claims 1-14

As above

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claim 1 is not fully supported by the description in that the claim does not include the presence of a cryoprotectant agent. The language of the description would appear to always include a cryoprotectant agent in the method of the invention.

Claim 6 lacks clarity because the cryoprotectant "Ficoll" has not been adequately identified.

Claim 13 lacks clarity. Claim 13 defines a method but it is appended to claim 10, which does not define a method.